Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Polycystic Ovary Syndrome 2Insulin Resistance 1

Interventions

Metformin 91Clomiphene 31Letrozole 23Inositol 19Folic Acid 11Chorionic Gonadotropin 11Exercise 10High-Intensity Interval Training 9drospirenone and ethinyl estradiol combination 8Ethinyl Estradiol 8Contraceptives, Oral 8Cholecalciferol 8cetrorelix 7Tablets 7Progesterone 7Menotropins 6follitropin alfa 5Pioglitazone 5Liraglutide 5Exenatide 5Cyproterone Acetate 5Caloric Restriction 5Vitamin D 4Triptorelin Pamoate 4Surveys and Questionnaires 4Sugars 4Spironolactone 4Glycoprotein Hormones, alpha Subunit 4Fish Oils 4Estradiol 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Polycystic Ovary Syndrome × DLBS3233 × Clear all
NCT01999686 2019-05-28

POSITIF

Dexa Medica Group

Phase 3 Completed
186 enrolled

Insulin Resistance, Polycystic Ovary Syndrome

NCT01733459 2018-07-26

Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)

Dexa Medica Group

Phase 3 Completed
124 enrolled

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡